<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733002</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-AGNH2018</org_study_id>
    <nct_id>NCT03733002</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.</brief_title>
  <acronym>AGNH2018</acronym>
  <official_title>Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cangzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Chengde Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AngongNiuhuang pill has obvious effects on the cardiovascular and cerebrovascular, especially&#xD;
      the cerebral vessels. Pharmacological experiments confirmed that AngongNiuhuang pill can&#xD;
      protect blood-brain barrier, reduce capillary permeability, improve the tolerance of cerebral&#xD;
      ischemia and hypoxia, improve oxidative stress injury, thus protecting brain tissue. Clinical&#xD;
      studies have also confirmed that AngongNiuhuang pill can increase the GCS score, reduce coma,&#xD;
      improve nerve function defect and promote nerve function recovery. The primary purpose of&#xD;
      this trial was to evaluate the effect of AngongNiuhuang pill and placebo on the improvement&#xD;
      of life function in patients with ischemic stroke at 90 days in acute phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, randomized, double-blinded, placebo parallel controlled,&#xD;
      multiple-center trial. A total of approximately 100 patients (18 years ≤age ≤80 years) within&#xD;
      24 hours of symptom onset of acute ischemic stroke, who shows NIHSS from 5-20 points.&#xD;
      Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be&#xD;
      randomized 1:1 into two groups after offering informed content: 1) one group will receive&#xD;
      AngongNiuhuang pill 1 pill 1 times/day for 5-day; 2) the other group will receive Placebo of&#xD;
      AngongNiuhuang pill 1 pill 1 times/day for 5-day.The primary purpose of this trial was to&#xD;
      evaluate the effect of AngongNiuhuang pill and placebo on the improvement of life function in&#xD;
      patients with ischemic stroke at 90 days in acute phase. The study consists of five visits&#xD;
      including the day of randomization, 2-6 days, monitor daily temperature, 7 days when the&#xD;
      therapy is done, 30 days, and 90 days when the follow-up is finished. Demographic&#xD;
      information, symptoms and signs, laboratory test, neuro-imaging assessment neurological&#xD;
      function rating scale will be recorded during the program. The improvement of life function&#xD;
      will be assessed by Modified Rankin Scale(namely score=0-2). The trial is anticipated to last&#xD;
      from July 2018 to December 2019 with 100 subjects recruited form 5 centers in China. All the&#xD;
      related investigative organization and individuals will obey the Declaration of Helsinki and&#xD;
      Chinese GCP standard. A Data and Safety Monitoring Board (DSMB) will regularly monitor safety&#xD;
      during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients achieve favorable clinical outcomes assessed by Modified Rankin Scale(namely score=0-2)</measure>
    <time_frame>90days</time_frame>
    <description>Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at the 90 days follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity Adverse Event</measure>
    <time_frame>90days</time_frame>
    <description>The percentage of the Severity Adverse Events within the 90 days of the therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieve favorable clinical outcomes assessed by Modified Rankin Scale(namely score=0-2)</measure>
    <time_frame>7days, 30days</time_frame>
    <description>Modified Rankin Scale score changes (continuous) and dichotomized at percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological recovery</measure>
    <time_frame>7 days, 30 days,90 days</time_frame>
    <description>The recovery of neurological deficits assessed by the change of the 7days, 30 days and the 90 days NIHSS to the baseline NIHSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>30 days, 90 days</time_frame>
    <description>Change in the score of the Barthel Index.（The Barthel Index (BI) measures 10 basic aspects of self-care and physical dependency, including 10 subscales: feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfers, mobility, and stairs. Every subscale ranges from 0 to 10. Its total score range is 0-100. A normal score is 100, and lower scores indicate increasing disability.）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent stroke, death and other vascular events</measure>
    <time_frame>30 days, 90 days</time_frame>
    <description>The quantity of patients who has recurrent stroke, death and other vascular events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of biomarker (hs-CRP)</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of the change in (centralization blood sample determination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of biomarker (IL-10)</measure>
    <time_frame>7days</time_frame>
    <description>Evaluation of the change in IL-10 (centralization blood sample determination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of biomarker (TNF-α)</measure>
    <time_frame>7days</time_frame>
    <description>Evaluation of the change in TNF-α level (centralization blood sample determination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>7 days, 90 days</time_frame>
    <description>The percentage of the Adverse Events during the therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Adverse Event</measure>
    <time_frame>7days</time_frame>
    <description>The percentage of the Severity Adverse Events during the therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>AngongNiuhuang</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of AngongNiuhuang</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AngongNiuhuang pill</intervention_name>
    <description>This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.</description>
    <arm_group_label>AngongNiuhuang</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of AngongNiuhuang pill</intervention_name>
    <description>This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.</description>
    <arm_group_label>Placebo of AngongNiuhuang</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>The other treatments according to guidelines for standard treatment of acute ischemic stroke.</description>
    <arm_group_label>AngongNiuhuang</arm_group_label>
    <arm_group_label>Placebo of AngongNiuhuang</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke.&#xD;
&#xD;
          2. 18 years ≤ age ≤ 80 years.&#xD;
&#xD;
          3. Within 24 hours from symptom onset.&#xD;
&#xD;
          4. Baseline NIHSS range 5 from 20.&#xD;
&#xD;
          5. Provision of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not suitable for taking this medicine after dialectic of traditional Chinese medical&#xD;
             doctor.&#xD;
&#xD;
          2. Suffering from intracranial tumors, encephalitis, subarachnoid hemorrhage and other&#xD;
             brain organic diseases.&#xD;
&#xD;
          3. Receive thrombolysis or endovascular treatment.&#xD;
&#xD;
          4. mRS&gt;1 at randomization (pre-morbid historical assessment).&#xD;
&#xD;
          5. Thrombocytopenia(&lt;100×10*9/L) , hematologic diseases and other systemic bleeding&#xD;
             tendency.&#xD;
&#xD;
          6. Sleepy head (GCS≤7).&#xD;
&#xD;
          7. Alanine transaminase &gt; 1.5 times normal upper limit or Aspartate aminotransferase &gt;&#xD;
             1.5 times normal upper limit.&#xD;
&#xD;
          8. Glomerular filtration rate&lt;60 ml/min/1.73m2.&#xD;
&#xD;
          9. Patients who have been taking AngongNiuhuang pills within 3 months.&#xD;
&#xD;
         10. Pregnancy or lactation, women in childbearing age with negative pregnancy test refuse&#xD;
             to accept contraception.&#xD;
&#xD;
         11. Participate in clinical studies of other research drugs within the last 30 days.&#xD;
&#xD;
         12. Patients with a life expectancy of less than three months.&#xD;
&#xD;
         13. Incapable to follow this study for mental illness, cognitive or emotional disorders.&#xD;
&#xD;
         14. Unsuitable for this study in the opinion of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Peng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengde Li, MD</last_name>
    <phone>86-17896002828</phone>
    <email>lishengde.medicine@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bin Peng, MD</last_name>
    <phone>86-10-69156371</phone>
    <email>pengbin3@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bin Peng</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shengde Li, MD</last_name>
      <phone>86-17896002828</phone>
      <email>lishengde.medicine@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Bin Peng, MD</last_name>
      <phone>86-10-69156371</phone>
      <email>pengbin3@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zunjing Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rusheng Shao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenzhong Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanjun Gao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Bin Peng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>AngongNiuhuang pill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

